MedPath

Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR)

Phase 3
Completed
Conditions
Chronic Sinusitis
Registration Number
NCT00231062
Lead Sponsor
Integra LifeSciences Corporation
Brief Summary

A multi-center, non-randomized, prospective post-market evaluation of sinuplasty in paranasal sinuses.

Detailed Description

Sinusitis is a common healthcare problem that significantly reduces quality of life for people around the world. Patients suffer from headache, facial discomfort, nasal congestion, nasal drainage, loss of the sense of smell and malaise. Sinusitis is responsible for major healthcare expenditure and loss of workplace productivity.

The rationale of this study is to collect data on the effectiveness and safety of balloon dilation of the Frontal, Maxillary and Sphenoid sinuses by treating patients and observing them for a six month period of time following the procedure. Six month follow-up data is important to demonstrate the effectiveness of balloon catheter dilation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
115
Inclusion Criteria
  1. Age 18 years and greater
  2. Both male and female patients eligible
  3. Diagnosis of chronic sinusitis that is not responsive to medical management
  4. Planned endoscopic sinus surgery (recommended by PI, consented to by patient)
Exclusion Criteria
  1. Extensive sinonasal polyps
  2. Extensive previous sinonasal surgery
  3. Extensive sinonasal osteoneogenesis
  4. Cystic fibrosis
  5. Sampter's Triad (Aspirin sensitivity, Asthma, Sinonasal polyposis)
  6. Sinonasal tumors or obstructive lesions
  7. History of facial trauma that distorts sinus anatomy and precludes access to the sinus ostium
  8. Ciliary dysfunction
  9. Pregnant females

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Number of Sinuses With Patency of Sinus Ostium After Sinuplasty24 weeks

Patency of sinus ostium after sinuplasty will be determined by nasal endoscopic examination. The investigator will make a clinical judgment as to whether or not this has been achieved.

Number of Participants With Adverse Events Following Sinuplasty Procedure24 weeks

Adverse event rate at 24 weeks: comprised of all observed peri-operative adverse events which were recorded on dedicated CRFs and any observed or patient-reported post-operative adverse events will be similarly recorded (through 24 week follow-up).

Secondary Outcome Measures
NameTimeMethod
Number of Participants Experiencing Relief of Sinus SymptomsWeek 24

To gain general insight into the ability of balloon catheter sinus ostial dilation to relieve sinus symptoms, scores from the pre-operative SNOT-20 evaluations were compared to scores from the post-procedure SNOT-20 evaluations at 24 weeks following the procedure. The number of participants who showed aggregate symptom relief are recorded here as having been successfully treated.

© Copyright 2025. All Rights Reserved by MedPath